Study S001099

Disposition of [14C]-Tirzepatide Following Subcutaneous Administration in Healthy Male Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT04311424
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 6
Start: 2020-07-28
Primary completion: 2020-10-02
Lead sponsor: Eli Lilly and Company
Conditions: Healthy
Interventions: DRUG:14C Tirzepatide
Results posted: TRUE
Individual participant data sharing: NO
Secondary identifiers: OTHER:I8F-MC-GPHX; EUDRACT_NUMBER:2019-003664-44; NIH:2019

Registered primary outcomes

Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered [Pre-dose and up to 63 days post-dose]
Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered [Pre-dose and up to 63 days post-dose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.